EUVIMEDEUVIMED entdecken
Crossref

Estimation of Treatment Effect in Clinical Trials of Continuous Endpoints With Retrieved Dropouts

Myeongjong Kang iD, Sangyoon Yi iD

Pharmaceutical Statistics · 2026

DOI: 10.1002/pst.70143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutical Statistics, 2026. Verfasst von Myeongjong Kang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Merck & Co. Inc., Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Patient Dropouts, Endpoint Determination, Models, Statistical. Die Arbeit nennt 27 Literaturangaben. Gefördert von: National Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The estimand framework provides guidance on handling intercurrent events in the analysis of clinical trial data. In this paper, we focus on treatment discontinuation as the intercurrent event of interest. Under ICH E9(R1), the treatment policy (TP) strategy evaluates clinical outcomes regardless of treatment discontinuation and therefore generally requires appropriate consideration of observed post‐discontinuation data. Existing approaches include likelihood‐based and imputation‐based methods for incorporating retrieved‐dropout (RD) data. We propose a likelihood‐based model for continuous endpoints that jointly represents outcomes among completers, RDs, and subjects lost to follow‐up within a unified parametric framework. The approach combines an analysis‐of‐covariance formulation with a probit model for treatment discontinuation, enabling treatment effects to be formulated explicitly for estimands that apply either the hypothetical or TP strategy to treatment discontinuation. Estimation is carried out via a computationally efficient maximum likelihood procedure. Numerical studies assess the performance of the proposed method relative to several alternative approaches, including settings in which the amount of observed RD data is limited.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicPatient DropoutsEndpoint DeterminationModels, StatisticalResearch DesignHumansTreatment OutcomeLikelihood FunctionsData Interpretation, Statistical

Stichwörter der Autor:innen

estimandhypothetical strategyretrieved dropouttreatment discontinuationtreatment policy strategy

Autor:innen und Institutionen

  • Merck & Co. Inc., Rahway, New Jersey, USA.
  • Department of Statistics, Oklahoma State University, Stillwater, Oklahoma, USA.

ORCID-Profile: Myeongjong Kang, Sangyoon Yi

Förderung

  • National Science Foundation

Zitieren

APA

Kang, M., & Yi, S. (2026). Estimation of Treatment Effect in Clinical Trials of Continuous Endpoints With Retrieved Dropouts. Pharmaceutical Statistics. https://doi.org/10.1002/pst.70143

Vancouver

Kang M, Yi S. Estimation of Treatment Effect in Clinical Trials of Continuous Endpoints With Retrieved Dropouts. Pharmaceutical Statistics. 2026. doi:10.1002/pst.70143

BibTeX
@article{Kang2026,
  author = {Kang, Myeongjong and Yi, Sangyoon},
  title = {Estimation of Treatment Effect in Clinical Trials of Continuous Endpoints With Retrieved Dropouts},
  journal = {Pharmaceutical Statistics},
  year = {2026},
  doi = {10.1002/pst.70143}
}
Kostenlos starten →